Four-year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation

Benjamin Miao1,2 | Adrian V. Hernandez1,2,3 | Yuani M. Roman2 | Mark J. Alberts4 | Craig I. Coleman1,2 | William L. Baker1,2

1University of Connecticut School of Pharmacy, Storrs, Connecticut, USA
2Hartford Hospital, Hartford, Connecticut, USA
3Vicerrectorado de Investigacion, Universidad San Ignacio de Loyola (USIL), Lima, Peru
4Neuroscience Institute, Hartford Hospital, Hartford, Connecticut, USA

Abstract

Background: There is a paucity of contemporary data assessing the implications of atrial fibrillation (AF) on major adverse cardiovascular events (MACE) in patients with or at high-risk for atherosclerotic disease managed in routine practice.

Hypothesis: We sought to evaluate the 4-year incidence of MACE in patients with or at risk of atherosclerotic disease in the presence of AF.

Methods: Using US MarketScan data, we identified AF patients ≥45 years old with billing codes indicating established coronary artery disease, cerebrovascular disease, or peripheral artery disease or the presence of ≥3 risk factors for atherosclerotic disease from January 1, 2013 to December 31, 2013 with a minimum of 4-years of available follow-up. We calculated the 4-year incidence of MACE (cardiovascular death or hospitalization with a primary billing code for myocardial infarction or ischemic stroke). Patients were further stratified by CHA2DS2-VASc score and oral anticoagulation (OAC) use at baseline.

Results: We identified 625,951 patients with 4-years of follow-up, of which 77,752 (12.4%) had comorbid AF. The median (25%, 75% range) CHA2DS2-VASc score was 4 (3, 5) and 64% of patients received an OAC at baseline. The incidence of MACE increased as CHA2DS2-VASc scores increased (P-interaction<.0001 for all). AF patients receiving an OAC were less likely to experience MACE (8.9% vs 11.6%, P < .0001) including ischemic stroke (5.4% vs 6.7%, P < .0001).

Conclusion: Comorbid AF carries a substantial risk of MACE in patients with or at risk of atherosclerotic disease. MACE risk increases with higher CHA2DS2-VASc scores and is more likely in patients without OAC.

Keywords
atrial fibrillation, established atherosclerotic disease, major adverse cardiovascular events

1 | INTRODUCTION

Atherosclerotic disease and atrial fibrillation (AF) share many of the same comorbidities and risk factors1 and frequently coexist. Compared to the general population, AF prevalence in patients with established atherosclerotic disease is fivefold higher (2.3% vs 11.7%, respectively).2 Both are independently associated with elevated major adverse cardiovascular events (MACE) risk and understanding the
synergistic increases in incidence rates and comparative risk based on disease characteristics may greatly aid treatment efforts by identifying patient factors associated with high risk.\(^3\) The Reduction of Atherothrombosis for Continued Health (REACH) registry prospectively evaluated patients at risk for or with established atherosclerotic disease.\(^4\) Subanalyses of REACH showed a 4-year MACE incidence of 24.3% in patients with comorbid AF.\(^3\) They also found a linear trend in the correlation between MACE and CHA\(_2\)DS\(_2\)VASc scores. However, REACH enrolled patients between 2003 and 2004 with follow-up through 2008. Advances in the management of AF in the past decade, such as the approval of non-vitamin K antagonist oral anticoagulants (NOAC) and their recommendation over warfarin in evidence-based guidelines, may have lowered MACE risk.\(^5\)-\(^7\) While the early hazard of MACE in AF patients has been previously evaluated, such studies only focused on incident AF patients and did not require patients to have atherosclerotic disease.\(^8\) It is therefore important to identify MACE incidence in a more contemporary population reflecting modern medical practices. This study aimed to estimate the contemporary 4-year incidence of MACE for United States AF patients with or at risk for established atherosclerotic disease in routine practice, the association between CHA\(_2\)DS\(_2\)-VASc scores and MACE risk, and how oral anticoagulation (OAC) use modifies this risk.

2 | METHODS

We performed a retrospective claims database analysis using US IBM MarketScan data from January 1, 2013 through December 31, 2017. MarketScan combines two separate databases, a commercial and a Medicare supplemental database, to cover all age groups; and contains claims from 260 contributing employers, 40 health plans, and government and public organizations representing ~240 million lives.\(^9\) MarketScan captures enrollment records, demographics, International Classification of Diseases, Tenth-Revision (ICD-10) diagnosis codes (and cross-walked ICD-9 codes), procedure codes, admission and discharge dates, outpatient medical services data, and prescription dispensing records. All MarketScan data are de-identified and are compliant with the Health Insurance Portability and Accountability Act of 1996. This study was determined by our institutional review board to not constitute research involving human subjects according to 45 Code of Federal Regulations 46.102(f) and was deemed exempt from board oversight.

We identified eligible patients according to similar criteria used for the REACH Registry by examining claims data between January 1, 2013 and December 31, 2013 (calendar year 2013). All patients \(\geq 45\)-years-of-age with comorbid AF (with or without valve disease) and established coronary artery disease (CAD; ie, diagnosis codes suggesting a history of stable or unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, or myocardial infarction), cerebrovascular disease (CVD; ie, diagnosis codes suggesting a history of ischemic stroke or transient ischemic attack) or peripheral artery disease (PAD; ie, diagnosis codes suggesting a history of peripheral arterial disease or a prior intervention including angioplasty, stenting, atherectomy, peripheral arterial bypass grafting, or amputations) or with three or more risk factors for atherosclerotic disease (ie, diagnosis codes suggesting a history of diabetes, diabetic nephropathy, carotid stenosis, hypertension, hypercholesterolemia, smoking, or age \(\geq 65\) years for men or \(\geq 70\) years for women) were included. Patients were further stratified by baseline CHA\(_2\)DS\(_2\)-VASc\(^{10}\) score and OAC use (apixaban, edoxaban, rivaroxaban, dabigatran, or warfarin).

Our main outcome measure was the incidence rate of MACE (composite outcome of cardiovascular mortality, myocardial infarction, or ischemic stroke). Secondary outcomes include individual MACE components. Cardiovascular mortality was defined as death occurring inhospital within 14 days of a myocardial infarction, ischemic stroke, heart failure, acute coronary syndrome, coronary artery bypass grafting, or percutaneous coronary intervention. Baseline data included demographics, vascular disease status, atherothrombotic risk factors, oral anticoagulants and other medications, and CHA\(_2\)DS\(_2\)-VASc scores. Patient selection, baseline characteristics, and outcome measure identification were based on the presence of ICD-10 (or cross-walked ICD-9) billing codes from medical and prescription claims. Starting on January 1, 2014, patients who met eligibility criteria during calendar year 2013 were followed for 4 years (patients with at least 3 years and 9 months of follow-up were included in the analysis) or until endpoint occurrence.

\(\text{FIGURE 1} \quad \text{Flow diagram of patient selection}\)
### TABLE 1  Baseline characteristics of patients with 4-years of follow-up

| Demographics (n, %) | Total established disease N = 36,398 | Any coronary artery diseasea N = 20,468 | Any cerebrovascular diseasea N = 10,128 | Any peripheral artery diseasea N = 13,256 | Multiple risk factors only N = 41,354 |
|---------------------|--------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|--------------------------------------|
| Age (median, 25%, 75% range) | 75 (68, 81) | 75 (67, 81) | 76 (69, 82) | 76 (69, 82) | 76 (70, 81) |
| Age ≥75 | 41,835 (53.8) | 19,148 (52.6) | 9988 (48.8) | 5675 (56.0) | 7520 (56.7) |
| Female | 32,047 (41.2) | 14,474 (39.8) | 7034 (34.4) | 4884 (48.2) | 5364 (40.5) |
| Risk factors (n, %) | | | | | |
| Diabetic nephropathy | 2167 (2.8) | 1008 (2.8) | 607 (3.0) | 267 (2.6) | 421 (3.2) |
| Carotid stenosis | 11,215 (14.4) | 6903 (19.0) | 3623 (17.7) | 2790 (27.5) | 2882 (21.7) |
| Hypercholesterolemia with treatment | 62,413 (80.3) | 26,804 (73.6) | 16,176 (79.0) | 7291 (72.0) | 9289 (70.1) |
| Smoker | 3828 (4.9) | 1960 (5.4) | 1203 (5.9) | 516 (5.1) | 802 (6.1) |
| Age ≥70 in females or ≥65 in males | 63,183 (81.3) | 28,073 (77.1) | 15,423 (75.4) | 7941 (78.4) | 10,695 (80.7) |
| Valvular diseaseb (n, %) | | | | | |
| Medication use (n, %) | | | | | |
| Oral anticoagulants | 49,694 (63.9) | 22,243 (61.1) | 12,065 (58.9) | 6477 (64.0) | 8271 (62.4) |
| Non-vitamin K oral anticoagulantsc | 16,060 (20.7) | 7286 (20.0) | 4014 (19.6) | 2230 (22.0) | 2525 (19.0) |
| Warfarinc | 36,280 (46.7) | 16,350 (44.9) | 8813 (43.1) | 4744 (46.8) | 6243 (47.1) |
| Antiarrhythmics | 18,542 (23.8) | 9008 (24.7) | 5979 (29.2) | 2066 (20.4) | 2867 (21.6) |
| Amiodarone | 9208 (11.8) | 5199 (14.3) | 3749 (18.3) | 1068 (10.5) | 1657 (12.5) |
| Dronedarone | 2467 (3.2) | 1142 (3.1) | 729 (3.6) | 245 (2.4) | 367 (2.8) |
| Other antiarrhythmic agents | 7917 (10.2) | 3221 (8.8) | 1889 (9.2) | 867 (8.6) | 999 (7.5) |
| Digoxin | 13,325 (17.1) | 5959 (16.4) | 3361 (16.4) | 1546 (15.3) | 2317 (17.5) |
| ACE/ARB | 48,964 (63.0) | 22,576 (62.0) | 13,428 (65.6) | 5967 (58.9) | 8072 (60.9) |
| ß-blockers | 57,513 (74.0) | 27,627 (75.9) | 16,610 (81.2) | 7271 (71.8) | 9775 (73.7) |
| Calcium channel blockers | 31,360 (40.3) | 14,211 (39.0) | 7777 (38.0) | 4269 (42.2) | 5307 (40.0) |
| Diuretics | 44,505 (57.2) | 21,118 (58.0) | 12,379 (60.5) | 5344 (52.8) | 8122 (61.3) |
| Antidiabetic agents | 24,888 (32.0) | 10,523 (28.9) | 6248 (30.5) | 2669 (26.4) | 4215 (31.8) |
| Statin | 59,305 (76.3) | 25,676 (70.5) | 15,568 (76.1) | 7023 (69.3) | 8834 (66.6) |
| P2Y12 inhibitors | 11,706 (15.1) | 8730 (24.0) | 6406 (31.3) | 2155 (21.3) | 2855 (21.5) |
| NSAIDs including COX-2 inhibitors | 11,726 (15.1) | 5510 (15.1) | 3150 (15.4) | 1482 (14.6) | 1984 (15.0) |

Abbreviations: ACE/ARB, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker; COX-2, cyclooxygenase-2 enzyme inhibitors; NSAID, nonsteroidal anti-inflammatory drugs.

*aThese cohorts overlap each other.

*bDefined according to the Elixhauser comorbidity index.

*cGroups are not mutually exclusive. Patients may have received both medications during the baseline period.
Baseline characteristics were analyzed using descriptive statistics. Categorical data are reported as percentages and continuous data as medians with accompanying 25%, 75% ranges. Outcomes are reported as cumulative proportions or incidences (i.e., events/patients) and incidence rates (i.e., events/100 person-years [PYs]). A multivariable Cox proportional hazard regression adjusting for known factors that influence cardiovascular outcomes (i.e., age, sex, smoking, chronic kidney disease, and statin use), components of the CHA₂DS₂-VASc score, medications relevant to the treatment and management of atherosclerotic disease and warfarin, NOAC or absence of OAC use was performed. The proportional hazards assumption was tested based on Schoenfeld residuals and was found to be valid for all outcomes. Associations are reported as adjusted hazard ratios (HRs) with 95% confidence intervals (CIs). The presence of statistical interactions of MACE across CHA₂DS₂-VASc scores were tested using the methods described by Altman and Bland. All data management and statistical analysis was performed using IBM SPSS Statistics version 25.0 (IBM Corp., Armonk, New York) and SAS 9.4 (SAS Institute Inc., Cary, North Carolina).

3 | RESULTS

We identified 625,951 patients with established atherosclerotic disease or ≥3-risk factors and 4-years of follow-up, of which 77,752 (12.4%) had comorbid AF (Figure 1). The patients with AF had a median (25%, 75% range) age of 75 (69, 81) years, CHA₂DS₂-VASc score was 4 (3, 5) and 26,921 (34.6%) had valvular disease. Patients with established atherosclerotic disease accounted for 46.8% of our population; among these, 56.2% had CAD, 27.8% had CVD, 36.4% had PAD, and 18.9% had polyvascular disease. The other 53.2% of the population had only ≥3-risk factors. Most patients had hypertension (98.5%) and hypercholesterolemia (80.3%) and just under half had diabetes. An angiotensin-converting enzyme inhibitor or angiotensin receptor blocker was used by 63% of patients, ~76% received a statin, ~15% a P2Y₁₂ inhibitor, ~74% a beta-blocker, ~64% an OAC, and ~24% an antiarrhythmic at baseline (Table 1).

Major adverse cardiovascular events occurred in 9.9% (2.95 events/100 PYs) of patients at 4-years, including an incidence of 11.6% (3.60 events/100 PYs) in patients with atherosclerotic disease and 8.4% (2.41 events/100 PYs) in patients with multiple risk factors only. Myocardial infarction, ischemic stroke and cardiovascular death occurred in 4.6% (1.34 events/100 PYs), 5.8% (1.71 events/100 PYs), and 1.6% (0.47 events/100 PYs) of patients, respectively. Among those with established disease, MACE incidences were the highest in patients with CVD (14.0%) followed by PAD (11.7%) and CAD (11.6%) (Table 2).

When the population was stratified based on CHA₂DS₂-VASc scores, the incidence of MACE and its individual components increased as scores increased (P-interaction <.001 for each outcome). MACE incidences ranged from 5.2% with a CHA₂DS₂-VASc score of 0% to 19.6% with a CHA₂DS₂-VASc score of 9 (Figure 2). Figure 3 shows incidences of MACE according to warfarin use, NOAC

| TABLE 2 | Incidences and rates of cardiovascular outcomes at 4-years |
| --- | --- |
| **MACE** | **Any coronary artery disease** |
| Total established disease | 2,952 (36.39 events/100PY (95% CI) n (%) | 2,952 (36.39 events/100PY (95% CI) n (%) |
| N = 77,752 events/100PY (95% CI) n (%) | 2,952 (36.39 events/100PY (95% CI) n (%) |
| 3.60 (3.49-3.71) | 4.34 (4.19-4.49) |
| **Any cerebrovascular disease** | **Any peripheral artery disease** |
| Total established disease | N = 36,398 events/100PY (95% CI) n (%) | N = 36,398 events/100PY (95% CI) n (%) |
| 2,952 (36.39 events/100PY (95% CI) n (%) | 2,952 (36.39 events/100PY (95% CI) n (%) |
| 3.60 (3.49-3.71) | 4.34 (4.19-4.49) |
| **Any coronary artery disease** | **Any cerebrovascular disease** | **Any peripheral artery disease** |
| N = 36,398 events/100PY (95% CI) n (%) | N = 36,398 events/100PY (95% CI) n (%) | N = 36,398 events/100PY (95% CI) n (%) |
| 2,952 (36.39 events/100PY (95% CI) n (%) | 2,952 (36.39 events/100PY (95% CI) n (%) | 2,952 (36.39 events/100PY (95% CI) n (%) |
| 3.60 (3.49-3.71) | 4.34 (4.19-4.49) | 4.34 (4.19-4.49) |
| **Myocardial infarction** | **Ischemic stroke** | **Cardiovascular-related death** |
| N = 77,752 events/100PY (95% CI) n (%) | N = 77,752 events/100PY (95% CI) n (%) | N = 77,752 events/100PY (95% CI) n (%) |
| 2,952 (36.39 events/100PY (95% CI) n (%) | 2,952 (36.39 events/100PY (95% CI) n (%) | 2,952 (36.39 events/100PY (95% CI) n (%) |
| 3.60 (3.49-3.71) | 4.34 (4.19-4.49) | 4.34 (4.19-4.49) |
| **Myocardial infarction** | **Ischemic stroke** | **Cardiovascular-related death** |
| N = 77,752 events/100PY (95% CI) n (%) | N = 77,752 events/100PY (95% CI) n (%) | N = 77,752 events/100PY (95% CI) n (%) |
| 2,952 (36.39 events/100PY (95% CI) n (%) | 2,952 (36.39 events/100PY (95% CI) n (%) | 2,952 (36.39 events/100PY (95% CI) n (%) |
| 3.60 (3.49-3.71) | 4.34 (4.19-4.49) | 4.34 (4.19-4.49) |
| **Myocardial infarction** | **Ischemic stroke** | **Cardiovascular-related death** |
| N = 77,752 events/100PY (95% CI) n (%) | N = 77,752 events/100PY (95% CI) n (%) | N = 77,752 events/100PY (95% CI) n (%) |
| 2,952 (36.39 events/100PY (95% CI) n (%) | 2,952 (36.39 events/100PY (95% CI) n (%) | 2,952 (36.39 events/100PY (95% CI) n (%) |
| 3.60 (3.49-3.71) | 4.34 (4.19-4.49) | 4.34 (4.19-4.49) |
| **Myocardial infarction** | **Ischemic stroke** | **Cardiovascular-related death** |
| N = 77,752 events/100PY (95% CI) n (%) | N = 77,752 events/100PY (95% CI) n (%) | N = 77,752 events/100PY (95% CI) n (%) |
| 2,952 (36.39 events/100PY (95% CI) n (%) | 2,952 (36.39 events/100PY (95% CI) n (%) | 2,952 (36.39 events/100PY (95% CI) n (%) |
| 3.60 (3.49-3.71) | 4.34 (4.19-4.49) | 4.34 (4.19-4.49) |

Abbreviations: CI, confidence interval; MACE, major adverse cardiovascular events; PY, person-years.
use or absence of OAC. Adjusted Cox regression analyses revealed similar results (Table 3). The presence of stage 3 or worse chronic kidney disease, diabetes and polyvascular disease were associated with a higher risk of MACE.

4 | DISCUSSION

In this large, contemporary real-world study of AF patients with or at risk for established atherosclerotic disease, MACE occurred in nearly 1 out of 10 patients at 4-years. AF patients experienced the highest rates of MACE if there was CVD involvement followed by PAD then CAD. Higher CHA2DS2-VASc scores were associated with increases in MACE development as well as its individual components. Compared to those that did not receive an OAC, OAC use was associated with reductions of 22%, 28%, 11%, and 14% in the incidences of MACE, myocardial infarction, ischemic stroke, and cardiovascular death, respectively.

Many of our results are consistent with those reported from the REACH registry studies, although differences do exist. The proportion of AF patients with or at risk for established atherosclerotic disease was similar: we reported 12.4% vs 10.3% reported in REACH.3 Incidences of MACE, however, differed. At 4-years, 24.3% of patients in REACH experienced MACE vs 9.9% in our study. Our study found
The reduction in stroke rates may be explained by the effectiveness of NOACs which were introduced after the completion of the REACH registry. Randomized controlled trials have shown that NOACs are at least non-inferior and, in some cases, superior to warfarin in preventing stroke and systemic embolism in non-valvular AF. In the updated 2019 American College of Cardiology/American Heart Association/Heart Rhythm Society guideline for management of AF and in the 2019 European Society of Cardiology guidelines for the diagnosis and management of chronic coronary syndromes, NOACs are recommended over warfarin in eligible patients with non-valvular AF (class I/level-of-evidence A recommendation). Although our study pooled NOACs and warfarin together, it captures an intermediary, real-world population during the gradual adoption of NOACs in comparison to the REACH population which predates the approval of NOACs. In addition to these changes, several modifications to the management of AF and atherosclerotic diseases have been made since the completion of the REACH registry. These include new long-term anticoagulation recommendations based on CHA2DS2-VASc scores and updates to American College of Cardiology/AHA guidelines which have recommended more intensive blood pressure control, increased usage of high-intensity statins and an increased scope and duration of treatment with dual antiplatelet therapy.

Other studies have also evaluated the association of risk factors and AF on MACE or its components. The GARFIELD-AF registry reported age, heart failure, prior stroke, vascular disease, moderate-to-severe chronic kidney disease, diabetes mellitus, and CHA2DS2-VASc score of ≥3 to be independent predictors of higher risk of early death. Although this is generally consistent with our findings, several differences between the studies exist. The prospective GARFIELD-AF registry focused on newly diagnosed (incident) AF patients and did not require patients to have atherosclerotic disease. Patients were also assessed for all-cause mortality, stroke/systemic embolism at 1-year of follow-up, whereas our study retrospectively evaluated MACE using a cardiovascular death definition in an AF population comorbid with atherosclerotic disease over 4-years of follow-up. Similarly, meta-analyses of PAD patients have found a significant association between AF and atherosclerotic disease over 4-years of follow-up. Similarly, meta-analyses of PAD patients have found a significant association between AF and atherosclerotic disease over 4-years of follow-up. Similarly, meta-analyses of PAD patients have found a significant association between AF and atherosclerotic disease over 4-years of follow-up.

### Table 3: Cox regression model of major adverse cardiovascular events at 4-years of follow-up

| Variables | HR (95% CI) |
|-----------|-------------|
| **Age (45-64 as referent)** | |
| 65-74 | 1.19 (1.09-1.29) |
| 75-84 | 1.90 (1.75-2.05) |
| ≥85 | 3.07 (2.81-3.35) |
| **Female** | 0.98 (0.94-1.03) |
| **Vascular beds (RFO as referent)** | |
| CAD only | 1.21 (1.14-1.29) |
| CVD only | 1.60 (1.48-1.73) |
| PAD only | 1.13 (1.05-1.22) |
| CAD + CVD | 1.58 (1.40-1.79) |
| CAD + PAD | 1.44 (1.29-1.59) |
| CVD + PAD | 1.68 (1.44-1.95) |
| CAD + CVD + PAD | 1.87 (1.53-2.28) |
| **Risk factors** | |
| Carotid stenosis | 1.01 (0.95-1.07) |
| CKD stage 3 or worse | 1.23 (1.15-1.31) |
| Congestive heart failure | 1.23 (1.17-1.30) |
| Diabetes | 1.11 (1.05-1.18) |
| Diabetic nephropathy | 1.08 (0.94-1.23) |
| Hypertension with treatment | 1.18 (0.95-1.46) |
| Hypercholesterolemia | 0.94 (0.83-1.06) |
| Smoker | 1.35 (1.22-1.49) |
| **Oral anticoagulation (none as referent)** | |
| Warfarin | 0.80 (0.76-0.85) |
| NOAC | 0.78 (0.73-0.84) |
| **Medications** | |
| ACEI or ARB | 1.02 (0.97-1.07) |
| β-blocker | 1.06 (1.01-1.12) |
| Calcium channel blocker | 1.04 (1.00-1.09) |
| Diuretics | 1.02 (0.97-1.08) |
| P2Y12 inhibitor | 1.29 (1.22-1.37) |
| Statin | 0.90 (0.81-1.01) |
| Metformin | 1.00 (0.94-1.07) |
| Alpha glucosidase inhibitor | 1.26 (0.84-1.89) |
| DPP4 inhibitors | 1.03 (0.93-1.13) |
| GLP1 agonists | 0.87 (0.71-1.06) |
| SGLT2 inhibitors | 1.73 (1.10-2.72) |
| Sulphonylureas or glinides | 1.07 (1.00-1.15) |
| Thiazolidinediones | 0.90 (0.76-1.07) |
| Insulin | 1.50 (1.40-1.61) |

Abbreviations: ACEI or ARB, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker; CAD, coronary artery disease; CI, confidence interval; CKD, chronic kidney disease; CVD, cerebrovascular disease; HR, hazard ratio; NOAC, non-vitamin K antagonist oral anticoagulants; PAD, peripheral artery disease; RFO, risk factors only.

similar myocardial infarction incidence compared to those of REACH (4.6% vs 4.9%, respectively) and lower ischemic stroke rates (5.8% vs 7.7%, respectively). The reduction in stroke rates may be explained by
the prevention of stroke and systemic embolism \(^{23,24}\) in AF. Compared to the REACH registry, which reported 54.2% of patients at baseline representing practice from 2003 to 2004,\(^3\) and to the GARFIELD-AF registry, which had 60.4% of patients prescribed anticoagulation therapy at baseline representing practice from 2010 to 2013 (cohorts 1 and 2),\(^{25}\) OAC adoption has improved over the years potentially explaining the lower ischemic stroke rates we observed.

Another driving factor for the difference in MACE incidences is the definition of cardiovascular death between studies. Our study utilized a 14-day grace period after a myocardial infarction, ischemic stroke, heart failure, acute coronary syndrome, coronary artery bypass grafting, or percutaneous coronary intervention for the occurrence of an in-hospital cardiovascular-related death. Our definition provides a conservative estimate of cardiovascular-related deaths given the limitations of claims data. In contrast, REACH captured cardiovascular deaths outside of hospital settings. This likely explains the lower 4-year MACE incidence in our study (1.6%) compared with REACH (10.6%).\(^3\)

This study has limitations worth discussing. First, misclassification bias must always be considered in claims database analyses and can detrimentally affect a study’s internal validity when present.\(^{26}\) Namely, our study only assessed OAC use at baseline and does not account for initiation during follow-up. Second, clinical adjudication of events was not possible within our claims database analysis. Of note, the REACH registry, while performed prospectively, also did not independently adjudicate outcomes. Third, antiplatelet agents, such as aspirin, are acquired over the counter and are difficult to track in claims data; however, OAC therapy is superior to antiplatelet therapy and is a mainstay in AF guidelines. Fourth, we were unable to differentiate between paroxysmal and persistent AF because our baseline period in 2013 used ICD-9 codes which do not make this distinction. Fifth, although we utilized a conservative definition of cardiovascular death which resulted in a smaller rate in comparison to that of REACH, survival bias cannot be ruled out. Finally, we used US commercial and Medicare supplemental plan claims data. As a consequence, our results are most generalizable to an insured US population with established or at high-risk for atherosclerotic disease.\(^9\)

5 | CONCLUSION

In conclusion, this large, contemporary real-world study demonstrates the impact of comorbid AF on MACE rates in patients with or at high-risk for atherosclerotic disease. We showed that increasing CHA\(_2\)DS\(_2\)-VASc scores were associated with higher MACE risk and a significant number of patients will experience a MACE by 4 years. OAC usage remains relatively low, although it may be increasing in recent years. Reductions in MACE risk may be attributed to changes in practice for AF management and the adoption of NOACs. These results emphasize the continued need for optimizing anticoagulant and antiplatelet therapy in AF patients at risk of or with atherosclerotic disease.

ACKNOWLEDGMENTS

Funding was provided by Bayer AG, Berlin, Germany and a Medical Staff Internal Grant from Hartford Hospital, Hartford, CT, USA. MarketScan data used in this study were obtained from the IBM under a third-party license agreement with Bayer AG, Berlin, Germany. The funder of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors have approved the final manuscript.

CONFLICTS OF INTEREST

B.M., A.V.H., N.M., Y.M.R., and W.L.B. declare they have no conflicts of interest. C.I.C. has received research funding and honoraria from Bayer AG, Janssen Scientific Affairs LLC, and Portola Pharmaceuticals, Inc. M.J.A. reports consultancy or speaker fees and honoraria from Genentech, Janssen Pharmaceuticals, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, Medscape, Portola and patents/royalties from Duke University. W.L.B. has received research funding from Portola Pharmaceuticals, Inc and consultancy fees from Bayer AG.

ORCID

Benjamin Miao https://orcid.org/0000-0002-2550-5027
William L. Baker https://orcid.org/0000-0003-2172-0931

REFERENCES

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121:948-954.
2. Goto S, Bhatt DL, Röther J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008;156:855-63, 863.e2.
3. Ruff CT, Bhatt DL, Steg PG, et al. Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. Int J Cardiol. 2014;170:413-418.
4. Ohman EM, Bhatt DL, Steg PG, et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006;151:786.e1-786.e10.
5. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-2962.
6. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74:104-132.
7. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2019;00:1-71.
8. Bassand JP, Virdone S, Goldhaber SZ, et al. Early risks of death, stroke/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation. Circulation. 2019;139:787-798.
9. Hansen L. The Truven Health MarketScan Databases for life sciences researchers. https://truvens.com/Portals/0/Assets/2017-MarketScan-Databases-Life-Sciences-Researchers-WP.pdf.
10. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using
11. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. *JAMA*. 2010;304:1350-1357.

12. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ*. 2003;326:219.

13. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2009;361:1139-1151.

14. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med*. 2011;365:883-891.

15. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2011;365:981-992.

16. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2013;369:2093-2104.

17. Levine GN, Bates ER, Bittl JA, et al. ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines; An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. *Circulation*. 2016;134:e123-55.

18. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2014;63:2889-2934.

19. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/ABC/ACP/AATS/AGS/APhA/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension*. 2018;71:e13-e115.

20. Vrsalovic M, Presecki AV. Atrial fibrillation and risk of cardiovascular events and mortality in patients with symptomatic peripheral artery disease: A meta-analysis of prospective studies. *Clin Cardiol*. 2017;40:1231-1235.

21. Vrsalovic M, Vucur K, Vrsalovic Presecki A, et al. Impact of diabetes on mortality in peripheral artery disease: a meta-analysis. *Clin Cardiol*. 2017;40:287-291.

22. Sen S, Dahlberg KW. Physician’s fear of anticoagulant therapy in nonvalvular atrial fibrillation. *Am J Med Sci*. 2014;348:513-521.

23. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. *Lancet*. 2006;367:1903-1912.

24. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. *N Engl J Med*. 2011;364:806-817.

25. Bassand JP, Accetta G, Camm AJ, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. *Eur Heart J*. 2016;37:2882-2889.

26. Gandhi SK, Salmon W, Kong SX, et al. Administrative databases and outcomes assessment: an overview of issues and potential utility. *J Manag Care Spec Pharm*. 1999;5:215-222.